Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

May 25, 2022

Study Completion Date

May 25, 2022

Conditions
Obesity
Interventions
BEHAVIORAL

Behavioral Treatment

Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).

DRUG

Placebo

The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.

DRUG

Phentermine 15 MG

The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.

Trial Locations (1)

19104

University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Pennsylvania

OTHER

NCT03779048 - Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment | Biotech Hunter | Biotech Hunter